Truist Securities Maintains Buy on OrthoPediatrics, Raises Price Target to $35-Report Released on 7th Nov
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter maintains a 'Buy' rating on OrthoPediatrics (NASDAQ:KIDS) and raises the price target from $31 to $35.
November 08, 2023 | 3:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities maintains a 'Buy' rating on OrthoPediatrics and raises the price target from $31 to $35, which could lead to a positive impact on the stock.
The raised price target by Truist Securities indicates a positive outlook for OrthoPediatrics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100